** Shares of Neurotech International NTI.AX rise as much as 10.6% to A$0.073, posting their biggest intraday percentage gain since Aug. 14
** Stock hits its highest level since Sept. 9
** Biopharmaceutical co says the U.S. Food and Drug Administration granted the orphan drug status to its NTI164 drug, aimed at treating Rett Syndrome
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** About 1.6 mln shares change hands, compared with the 30-day average volume of around 601,000
** Stock up 1.5% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.